Estrella Immunopharma, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Estrella Immunopharma received a notice of failure to satisfy continued listing rules or standards, triggering Item 3.01 disclosure of potential delisting or listing transfer. No specific non-compliance detail, remediation plan, or timeline is provided in this filing stub. The notice represents a critical regulatory/compliance event for the company.
Why this rating
Delisting risk is existential for $20.5M public company. Threatens market access, financing, and investor confidence regardless of remediation outcome.
Extracted items
Tradability signal
NO TRADE
No trade: price $0.07 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $0.07 | +10 min · unknown $0.07 ▲ 0.00% | +30 min · unknown $0.07 ▲ 0.00% | +1 hr · unknown $0.07 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.